S3070 Epidemiology and Baseline Characteristics of Patients With Gastrointestinal Stromal Tumors: A Population-Based Study in the United States

Introduction: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal cancer of the gastrointestinal tract (GIT), with a peak incidence at the age of 60-74 years. Their overall global incidence has been estimated as 10-20 per million, accounting for approximately 1%–2% of the total GIT malignancies. Understanding the baseline demographics and comorbidities of GISTs can enhance early recognition, risk stratification, and management. Methods: We conducted a retrospective descriptive study using TriNetX, a global database of de-identified electronic patients' health records. Adults aged 18 years and older with a confirmed diagnosis of gastrointestinal stromal tumor (GIST), identified by International Classification of Diseases-10 code (C49.A), between October 2015 and May 2025, were included. Demographics (age, sex, race, ethnicity) and baseline comorbidities were analysed. Results: Our data showed that out of 153,382,260 patients screened in TriNetX, 22,576 individuals had a diagnosis of GIST with overall prevalence of 15 cases per 100,000 and a mean age of 64.9 years (±13.5) at diagnosis, females comprised 50.6% of the sample. Racially, 60% of our sample were White, 19% were Black or African American, 7% Asian, and 3.5% from other races, with 9% unspecified. Common comorbidities were analysed including hypertensive diseases (46%), diabetes mellitus (19%), and ischemic heart diseases (13.4%). Obesity or overweight status was recorded in 15%, liver disease in 13.1%, and nicotine dependence in 12%. Chronic kidney disease affected 9% of patients. Less common but potentially relevant comorbidities was analysed in our study such as alcohol-related disorders (2%), ulcerative colitis (0.7%), Crohn’s disease (0.6%), acute pancreatitis (1%) and chronic pancreatitis (0.7%). Conclusion: In this large United States GIST sample, age and gender composition matched the existing data in the literature suggesting no significant gender predominance and a mean age at diagnosis of >60. Additionally, as reported by previously established data, our study shows that cardiometabolic comorbidities are frequently co-reported in GIST patients. These findings reinforce the importance of holistic risk stratification strategies and further epidemiologic monitoring for GIST cases.